Cantor Fitzgerald Predicts Higher Earnings for MannKind

MannKind Co. (NASDAQ:MNKD) – Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of MannKind in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $0.23 per share for the year, up from their previous forecast of $0.18. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Several other analysts have also commented on MNKD. Mizuho assumed coverage on shares of MannKind in a report on Thursday, April 10th. They issued an “outperform” rating and a $12.00 price objective for the company. StockNews.com raised shares of MannKind from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of MannKind in a report on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.00.

MannKind Stock Down 0.2%

Shares of MNKD stock opened at $4.56 on Wednesday. The stock has a fifty day moving average of $4.86 and a 200 day moving average of $5.78. MannKind has a 52 week low of $4.34 and a 52 week high of $7.63. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 65.14 and a beta of 1.14.

MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $78.35 million for the quarter, compared to analysts’ expectations of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.05 earnings per share.

Insider Transactions at MannKind

In other MannKind news, EVP David Thomson sold 32,179 shares of the company’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total value of $150,597.72. Following the completion of the sale, the executive vice president now owns 772,427 shares in the company, valued at $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Steven B. Binder sold 80,144 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $4.69, for a total value of $375,875.36. Following the completion of the transaction, the director now directly owns 1,006,611 shares in the company, valued at $4,721,005.59. This trade represents a 7.37% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of MannKind during the fourth quarter worth $37,000. Jones Financial Companies Lllp boosted its holdings in shares of MannKind by 3,294.8% during the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 6,392 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new position in shares of MannKind during the fourth quarter valued at about $65,000. Blueshift Asset Management LLC purchased a new position in shares of MannKind during the first quarter valued at about $51,000. Finally, Beirne Wealth Consulting Services LLC bought a new stake in shares of MannKind in the fourth quarter worth about $66,000. 49.55% of the stock is owned by hedge funds and other institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.